Tiagabine and the treatment of refractory bipolar disorder.
Schaffer
L C
LC
Schaffer
C B
CB
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000517:prevention & control / Q000523:psychology; D004334:Drug Administration Schedule; D017277:Drug Approval; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D009557:Nipecotic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D011619:Psychotropic Drugs / Q000008:administration & dosage / Q000627:therapeutic use; D055502:Secondary Prevention; D000078308:Tiagabine; D014481:United States; D014486:United States Food and Drug Administration
D000927:Anticonvulsants; D009557:Nipecotic Acids; D011619:Psychotropic Drugs; D000078308:Tiagabine